Onchilles Pharma’s (potentially) Groundbreaking Pan-Cancer Therapeutics: Targeting the ELANE Pathway
/0 Comments/in Immunotherapy, Preclinical Research/by MaxEarly PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer
/0 Comments/in Post-hoc, Retrospective studies/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxA Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPSA Kinetics Predict Survival Outcomes in High-Volume Metastatic Prostate Cancer
/0 Comments/in Retrospective studies/by MaxBreaking Barriers: FDA Approval of Tecelra Marks a New Era for TCR Therapy in Solid Tumors
/0 Comments/in Not PCa related/by MaxNot related to prostate cancer but really interesting: allogenic CAR-T is getting good results!
/0 Comments/in Not PCa related/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent June 12, 2025
- Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials June 11, 2025
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025